Small Is Big: New Vscan Technology May Replace The Stethoscope
GE’s drive to miniaturize technologies in order to make them more mobile couldn’t be better illustrated than with the breakthrough Vscan technology…
chembio diagnostics
FDA to Collaborate with Pharma Companies on New TB Initiative
A number of pharmaceutical companies will collaborate with FDA scientists to test new TB combination therapies and identify promising candidates.
Chembio Diagnostics Tackles Infectious Diseases with Rapid-Diagnostic Platform
Chembio Diagnostics specializes in the development of advanced diagnostic tests for infectious diseases such as HIV and syphilis.
Chembio Diagnostics at the 2010 OneMedForum
Lawrence A. Siebert, President and CEO of Chembio Diagnostics, discusses his company with OneMedTV correspondent Alicia Ontiveros at the 2010 OneMedForum in San Francisco.
Two Studies Show Potential for Treating Drug-Resistant TB
Tuberculosis, or TB, is one of the world’s most widespread lethal diseases, killing someone every 20 seconds. An estimated one-third of the world’s population is infected with tuberculosis. Current medications for TB must be taken for six months, but many patients stop before they’ve completed the full course, which has caused drug-resistant strains of TB to develop in recent years. However, two new studies are showing promise in treating this highly infectious disease.
According to Science Daily, the Albert Einstein College of Medicine at Yeshiva University found that a combination of two FDA-approved antibiotics showed potential for treating drug-resistant TB. One of the drugs, clavulanate, inhibits a bacterial enzyme that normally protects TB bacteria from the other antibiotic (meropenem). Clinical trials of the combined treatment are scheduled to take place later this year in South Africa and South Korea.